comparemela.com

Latest Breaking News On - Xurion aktie - Page 1 : comparemela.com

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program: Eleventh tranche fully issued and paid-up

10.04.2024 - Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, .

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

20.11.2023 -   Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has Decided to Take Necessary Steps to File for Bankruptcy Leuven, BELGIUM, Boston, MA, US – November . Seite 1

Oxurion Receives EUR 1 5 Million under Amended Atlas Funding Program; Total of EUR 3 5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial

25.10.2023 - Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal .

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.